Skip to content
OpenCapital
Get started

Rein Therapeutics Inc. RNTX Q1 2026 Annual earnings

Reported May 15, 2026 · Before market open

Revenue-Diluted EPS-$0.19Beat by $0.30
EPS estimate-$0.49

Next report

Aug 13, 2026 (in a month)
EPS estimate-$0.27

Financials

Q1 2026

Income statement

See full
Revenue-—
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%

Versus estimates

Diluted EPS

Q1 2026-$0.19Beat by $0.30
Q4 2025-$1.09In lineQ3 2025-$0.21Beat by $0.03Q2 2025-$0.28Miss by $0.06Q1 2025-$0.26Miss by $0.12Q4 2024-$1.89Miss by $1.43

Ask the moment Rein Therapeutics Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Rein Therapeutics Inc. report Q1 2026 earnings?
Rein Therapeutics Inc. (RNTX) reported Q1 2026 earnings on May 15, 2026 before market open.
What were Rein Therapeutics Inc.'s Q1 2026 revenue and EPS?
Rein Therapeutics Inc. reported revenue of - and diluted EPS of $-0.19 for Q1 2026.
Did Rein Therapeutics Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.49 by $0.30.
How did Rein Therapeutics Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 26.9% from $-0.26.
Where can I find Rein Therapeutics Inc.'s Q1 2026 SEC filings?
You can read the 10-K/A periodic report (0001193125-26-178787) directly on SEC EDGAR. The filing index links above go to sec.gov.